Howard L Weiner

List of Publications by Year in Descending Order

215 papers	17,225 citations	60 h-index	129 g-index
230 ext. papers	20,908 ext. citations	10.1 avg, IF	6.91 L-index

#	Paper	IF	Citations
215	Temporal trends of multiple sclerosis disease activity: Electronic health records indicators.. *Multiple Sclerosis and Related Disorders*, **2022**, 57, 103333	4	0
214	Targeting Epstein-Barr virus to treat MS.. *Med*, **2022**, 3, 159-161	31.7	
213	How does Epstein-Barr virus trigger MS?. *Immunity*, **2022**, 55, 390-392	32.3	2
212	The microbiota restrains neurodegenerative microglia in a model of amyotrophic lateral sclerosis.. *Microbiome*, **2022**, 10, 47	16.6	0
211	Oral tolerance: an updated review.. *Immunology Letters*, **2022**, 245, 29-37	4.1	2
210	Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis.. *Multiple Sclerosis and Related Disorders*, **2022**, 62, 103793	4	0
209	Proximal and distal effects of genetic susceptibility to multiple sclerosis on the T cell epigenome. *Nature Communications*, **2021**, 12, 7078	17.4	3
208	Widespread Glial Activation in Primary Progressive Multiple Sclerosis Revealed by 18F-PBR06 PET: A Clinically Feasible, Individualized Approach. *Clinical Nuclear Medicine*, **2021**, 46, 136-137	1.7	1
207	Comparison of Dimethyl Fumarate vs Fingolimod and Rituximab vs Natalizumab for Treatment of Multiple Sclerosis. *JAMA Network Open*, **2021**, 4, e2134627	10.4	3
206	Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis. *Quality of Life Research*, **2021**, 1	3.7	0
205	Myeloid cell subsets that express latency-associated peptide promote cancer growth by modulating T□cells. *IScience*, **2021**, 24, 103347	6.1	0
204	Gut Microbiome in Progressive Multiple Sclerosis. *Annals of Neurology*, **2021**, 89, 1195-1211	9.4	27
203	Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2021**, 7, 2055217321999070	2	0
202	Regulation of splenic monocyte homeostasis and function by gut microbial products. *IScience*, **2021**, 24, 102356	6.1	0
201	Relapse recovery in multiple sclerosis: Effect of treatment and contribution to long-term disability. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2021**, 7, 20552173211015503	2	1
200	The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2021**, 7, 20552173211007523	2	
199	Validation of Two Kinetic Assays for the Quantification of Endotoxin in Human Serum. *Frontiers in Neurology*, **2021**, 12, 691683	4.1	1

198	Obesity is associated with the Optic Neuritis severity in Male patients with Multiple Sclerosis. *Multiple Sclerosis and Related Disorders*, **2021**, 51, 102910	4	
197	Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis. *Multiple Sclerosis Journal*, **2021**, 27, 593-602	5	4
196	MRI Lesion State Modulates the Relationship Between Serum Neurofilament Light and Age in Multiple Sclerosis. *Journal of Neuroimaging*, **2021**, 31, 388-393	2.8	3
195	PD-L1 and XCR1 dendritic cells are region-specific regulators of gut homeostasis. *Nature Communications*, **2021**, 12, 4907	17.4	5
194	Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study. *Frontiers in Immunology*, **2021**, 12, 709861	8.4	1
193	Review of Phase III Clinical Trials Outcomes in Patients with Secondary Progressive Multiple Sclerosis. *Multiple Sclerosis and Related Disorders*, **2021**, 54, 103086	4	1
192	Serum neurofilament levels and patient-reported outcomes in multiple sclerosis. *Annals of Clinical and Translational Neurology*, **2021**, 8, 631-638	5.3	3
191	Blood neurofilament light: a critical review of its application to neurologic disease. *Annals of Clinical and Translational Neurology*, **2020**, 7, 2508-2523	5.3	39
190	Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. *Annals of Clinical and Translational Neurology*, **2020**, 7, 945-955	5.3	15
189	COVID-19 in teriflunomide-treated patients with multiple sclerosis. *Journal of Neurology*, **2020**, 267, 2790-2796	5.3	37
188	Serum antibodies to phosphatidylcholine in MS. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	3
187	Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study. *Journal of Neuroimaging*, **2020**, 30, 212-218	2.8	4
186	Protein Degradome of Spinal Cord Injury: Biomarkers and Potential Therapeutic Targets. *Molecular Neurobiology*, **2020**, 57, 2702-2726	6.2	7
185	Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2020**, 40, 101944	4	2
184	The microbiome requires a genetically susceptible host to induce central nervous system autoimmunity. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 27764-27766	11.5	1
183	7T MRI cerebral leptomeningeal enhancement is common in relapsing-remitting multiple sclerosis and is associated with cortical and thalamic lesions. *Multiple Sclerosis Journal*, **2020**, 26, 177-187	5	28
182	An argument for broad use of high efficacy treatments in early multiple sclerosis. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	26
181	Social support in multiple sclerosis: Associations with quality of life, depression, and anxiety. *Journal of Psychosomatic Research*, **2020**, 138, 110252	4.1	11

180	Ensemble learning predicts multiple sclerosis disease course in the SUMMIT study. *Npj Digital Medicine*, **2020**, 3, 135	15.7	6
179	A One-Two Punch in the Gut May Trigger Multiple Sclerosis. *Immunity*, **2020**, 53, 707-709	32.3	1
178	Aberrant expression of USF2 in refractory rheumatoid arthritis and its regulation of proinflammatory cytokines in Th17 cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 30639-30648	11.5	11
177	Regional microglial activation in the substantia nigra is linked with fatigue in MS. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	3
176	Improved relapse recovery in paediatric compared to adult multiple sclerosis. *Brain*, **2020**, 143, 2733-2741	11.2	20
175	Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. *Neurology: Neuroimmunology and NeuroInflammation*, **2020**, 7,	9.1	9
174	A pharmacogenetic study implicates in the response to Interferon-β in multiple sclerosis. *Multiple Sclerosis Journal*, **2020**, 26, 1074-1082	5	1
173	Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression. *Multiple Sclerosis Journal*, **2020**, 26, 1708-1718	5	15
172	The sex-specific interaction of the microbiome in neurodegenerative diseases. *Brain Research*, **2019** , 1724, 146385	3.7	11
171	Visualizing Lymph Node Structure and Cellular Localization using Ex-Vivo Confocal Microscopy. *Journal of Visualized Experiments*, **2019**,	1.6	3
170	Latent-period stool proteomic assay of multiple sclerosis model indicates protective capacity of host-expressed protease inhibitors. *Scientific Reports*, **2019**, 9, 12460	4.9	4
169	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. *Science*, **2019**, 365,	33.3	309
168	The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis. *Journal of the Neurological Sciences*, **2019**, 403, 38-43	3.2	10
167	Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis. *Crohn's & Colitis 360*, **2019**, 1, otz009	1.4	6
166	Mucosal tolerance therapy in humans: Past and future. *Clinical and Experimental Neuroimmunology*, **2019**, 10, 20-31	0.4	3
165	MRI phenotypes in MS: Longitudinal changes and miRNA signatures. *Neurology: Neuroimmunology and NeuroInflammation*, **2019**, 6, e530	9.1	11
164	Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients. *Multiple Sclerosis Journal - Experimental, Translational and Clinical*, **2019**, 5, 2055217319828400	2	4
163	Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. *Nature Neuroscience*, **2019**, 22, 729-740	25.5	166

162	Time between expanded disability status scale (EDSS) scores. *Multiple Sclerosis and Related Disorders*, **2019**, 30, 98-103	4	7
161	Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. *Multiple Sclerosis and Related Disorders*, **2019**, 35, 119-127	4	13
160	Gray matter microglial activation in relapsing vs progressive MS: A [F-18]PBR06-PET study. *Neurology: Neuroimmunology and NeuroInflammation*, **2019**, 6, e587	9.1	15
159	History of fatigue in multiple sclerosis is associated with grey matter atrophy. *Scientific Reports*, **2019**, 9, 14781	4.9	13
158	T Cell-Secreted XCL1 Mediates Anti-CD3-Induced Oral Tolerance. *Journal of Immunology*, **2019**, 203, 2621-2629	5.3	10
157	Calorie restriction slows age-related microbiota changes in an Alzheimer's disease model in female mice. *Scientific Reports*, **2019**, 9, 17904	4.9	47
156	Oral Administration of miR-30d from Feces of MS Patients Suppresses MS-like Symptoms in Mice by Expanding Akkermansia muciniphila. *Cell Host and Microbe*, **2019**, 26, 779-794.e8	23.4	56
155	Quantifying neurologic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. *Npj Digital Medicine*, **2019**, 2, 123	15.7	21
154	Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis. *Multiple Sclerosis Journal*, **2019**, 25, 1791-1799	5	1
153	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. *Multiple Sclerosis Journal*, **2019**, 25, 1605-1617	5	46
152	Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells. *Multiple Sclerosis Journal*, **2019**, 25, 63-71	5	13
151	Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. *Muscle and Nerve*, **2018**, 58, 261-269	3.4	52
150	Multiple Sclerosis: Mechanisms and Immunotherapy. *Neuron*, **2018**, 97, 742-768	13.9	348
149	A probiotic modulates the microbiome and immunity in multiple sclerosis. *Annals of Neurology*, **2018**, 83, 1147-1161	9.4	97
148	Systematic evaluation of RNA quality, microarray data reliability and pathway analysis in fresh, fresh frozen and formalin-fixed paraffin-embedded tissue samples. *Scientific Reports*, **2018**, 8, 6351	4.9	46
147	Microbiota Signaling Pathways that Influence Neurologic Disease. *Neurotherapeutics*, **2018**, 15, 135-145	6.4	67
146	Investigation of probiotics in multiple sclerosis. *Multiple Sclerosis Journal*, **2018**, 24, 58-63	5	58
145	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. *Multiple Sclerosis Journal*, **2018**, 24, 1485-1498	5	14

144	Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis. *ENeurologicalSci*, **2018**, 12, 42-46	2.1	9
143	Identification of MS-specific serum miRNAs in an international multicenter study. *Neurology: Neuroimmunology and NeuroInflammation*, **2018**, 5, e491	9.1	34
142	T cells control humoral immune response by inducing T follicular helper cell differentiation. *Nature Communications*, **2018**, 9, 3151	17.4	25
141	Microglia inhibit photoreceptor cell death and regulate immune cell infiltration in response to retinal detachment. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E6264-E6273	11.5	60
140	Cellular Components and Mechanisms of Oral Tolerance Induction. *Critical Reviews in Immunology*, **2018**, 38, 207-231	1.8	5
139	Dominant role of microglial and macrophage innate immune responses in human ischemic infarcts. *Brain Pathology*, **2018**, 28, 791-805	6	58
138	Dual-Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI. *Journal of Neuroimaging*, **2018**, 28, 36-47	2.8	27
137	Acute microglia ablation induces neurodegeneration in the somatosensory system. *Nature Communications*, **2018**, 9, 4578	17.4	31
136	Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. *Annals of Clinical and Translational Neurology*, **2018**, 5, 1478-1491	5.3	69
135	Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate. *Journal of the Neurological Sciences*, **2018**, 394, 127-131	3.2	7
134	Microglial signatures and their role in health and disease. *Nature Reviews Neuroscience*, **2018**, 19, 622-635	33.5	287
133	An immunoregulatory and tissue-residency program modulated by c-MAF in human T17 cells. *Nature Immunology*, **2018**, 19, 1126-1136	19.1	52
132	A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. *International Journal of Neuroscience*, **2017**, 127, 396-403	2	8
131	Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity. *JAMA Neurology*, **2017**, 74, 275-285	17.2	37
130	Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis. *International Journal of Neuroscience*, **2017**, 127, 971-980	2	10
129	Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. *Journal of Neuroimaging*, **2017**, 27, 481-485	2.8	23
128	Survivin controls biogenesis of microRNA in smokers: A link to pathogenesis of rheumatoid arthritis. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2017**, 1863, 663-673	6.9	8
127	Targeting latency-associated peptide promotes antitumor immunity. *Science Immunology*, **2017**, 2,	28	41

126	Loss of 'homeostatic' microglia and patterns of their activation in active multiple sclerosis. *Brain*, **2017**, 140, 1900-1913	11.2	296
125	IL-6 Inhibits Upregulation of Membrane-Bound TGF-□1 on CD4+ T Cells and Blocking IL-6 Enhances Oral Tolerance. *Journal of Immunology*, **2017**, 198, 1202-1209	5.3	12
124	The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. *Immunity*, **2017**, 47, 566-581.e9	32.3	988
123	Disruption of the ATP/adenosine balance in CD39 mice is associated with handling-induced seizures. *Immunology*, **2017**, 152, 589-601	7.8	17
122	Oral treatment with foralumab, a fully human anti-CD3 monoclonal antibody, prevents skin xenograft rejection in humanized mice. *Clinical Immunology*, **2017**, 183, 240-246	9	10
121	History and mechanisms of oral tolerance. *Seminars in Immunology*, **2017**, 30, 3-11	10.7	39
120	A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. *Journal of the Neurological Sciences*, **2017**, 383, 221-229	3.2	13
119	Transcriptional signature of human pro-inflammatory T17 cells identifies reduced IL10 gene expression in multiple sclerosis. *Nature Communications*, **2017**, 8, 1600	17.4	62
118	Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2017**, 18, 196-201	4	12
117	Dynamic regulation of serum aryl hydrocarbon receptor agonists in MS. *Neurology: Neuroimmunology and NeuroInflammation*, **2017**, 4, e359	9.1	24
116	The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2017**, 17, 47-53	4	12
115	Mucosal administration of CD3-specific monoclonal antibody inhibits diabetes in NOD mice and in a preclinical mouse model transgenic for the CD3 epsilon chain. *Journal of Autoimmunity*, **2017**, 76, 115-122	15.5	11
114	The emergence of neuroepidemiology, neurovirology and neuroimmunology: the legacies of John F. Kurtzke and Richard 'Dick' T. Johnson. *Journal of Neurology*, **2017**, 264, 817-828	5.5	1
113	Exploration of machine learning techniques in predicting multiple sclerosis disease course. *PLoS ONE*, **2017**, 12, e0174866	3.7	71
112	IL-10-dependent Tr1 cells attenuate astrocyte activation and ameliorate chronic central nervous system inflammation. *Brain*, **2016**, 139, 1939-57	11.2	62
111	Alterations of the human gut microbiome in multiple sclerosis. *Nature Communications*, **2016**, 7, 12015	17.4	632
110	AHR Activation Is Protective against Colitis Driven by T Cells in Humanized Mice. *Cell Reports*, **2016**, 17, 1318-1329	10.6	97
109	Power estimation for non-standardized multisite studies. *NeuroImage*, **2016**, 134, 281-294	7.9	28

108	Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. *Immunotherapy*, **2016**, 8, 889-906	3.8	92
107	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2016**, 387, 1075-1084	40	271
106	The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. *Journal of Neuroimaging*, **2016**, 26, 184-7	2.8	11
105	Serum lipid antibodies are associated with cerebral tissue damage in multiple sclerosis. *Neurology: Neuroimmunology and NeuroInflammation*, **2016**, 3, e200	9.1	24
104	Immunology. How does the immune system tolerate food?. *Science*, **2016**, 351, 810-1	33.3	11
103	The Host Shapes the Gut Microbiota via Fecal MicroRNA. *Cell Host and Microbe*, **2016**, 19, 32-43	23.4	394
102	Control of the gut microbiome by fecal microRNA. *Microbial Cell*, **2016**, 3, 176-177	3.9	32
101	Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk. *Annals of Neurology*, **2016**, 79, 178-89	9.4	30
100	Inducing tolerance one antigen at a time. *Nature Biotechnology*, **2016**, 34, 515-7	44.5	1
99	Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. *Neurology: Neuroimmunology and NeuroInflammation*, **2016**, 3, e267	9.1	50
98	Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis. *NeuroImage*, **2015**, 119, 81-8	7.9	6
97	A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity. *Annals of Neurology*, **2015**, 78, 115-27	9.4	33
96	Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. *JAMA Neurology*, **2015**, 72, 152-8	17.2	260
95	Platelets Play Differential Role During the Initiation and Progression of Autoimmune Neuroinflammation. *Circulation Research*, **2015**, 117, 779-92	15.7	49
94	Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. *Journal of Neurology*, **2015**, 262, 2425-32	5.5	19
93	ISDN2014_0027: REMOVED: Identification of a unique molecular and functional microglia signature in health and disease. *International Journal of Developmental Neuroscience*, **2015**, 47, 5-5	2.7	1
92	ISDN2014_0028: REMOVED: Targeting miR-155 restores dysfunctional microglia and ameliorates disease in the SOD1 model of ALS. *International Journal of Developmental Neuroscience*, **2015**, 47, 5-5	2.7	1
91	Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models. *NeuroImage: Clinical*, **2015**, 8, 606-10	5.3	19

90	In vivo anti-LAP mAb enhances IL-17/IFN- responses and abrogates anti-CD3-induced oral tolerance. *International Immunology*, **2015**, 27, 73-82	4.9	14
89	Meeting report: discussions and preliminary findings on extracellular RNA measurement methods from laboratories in the NIH Extracellular RNA Communication Consortium. *Journal of Extracellular Vesicles*, **2015**, 4, 26533	16.4	45
88	Extracellular RNAs: development as biomarkers of human disease. *Journal of Extracellular Vesicles*, **2015**, 4, 27495	16.4	54
87	Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation. *Journal of Neuroinflammation*, **2015**, 12, 245	10.1	23
86	Pathogenic Transdifferentiation of Th17 Cells Contribute to Perpetuation of Rheumatoid Arthritis during Anti-TNF Treatment. *Molecular Medicine*, **2015**, 21, 536-43	6.2	20
85	Effect of vitamin D on MS activity by disease-modifying therapy class. *Neurology: Neuroimmunology and NeuroInflammation*, **2015**, 2, e167	9.1	34
84	Identification and characterization of latency-associated peptide-expressing T cells. *Nature Communications*, **2015**, 6, 8726	17.4	23
83	Evaluating more naturalistic outcome measures: A 1-year smartphone study in multiple sclerosis. *Neurology: Neuroimmunology and NeuroInflammation*, **2015**, 2, e162	9.1	33
82	Identification of a unique TGF- dependent molecular and functional signature in microglia. *Nature Neuroscience*, **2014**, 17, 131-43	25.5	1532
81	MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis. *Journal of the Neurological Sciences*, **2014**, 346, 250-4	3.2	23
80	An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. *Multiple Sclerosis Journal*, **2014**, 20, 1381-90	5	24
79	Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation. *Nature Medicine*, **2014**, 20, 1147-56	50.5	267
78	Differential roles of microglia and monocytes in the inflamed central nervous system. *Journal of Experimental Medicine*, **2014**, 211, 1533-49	16.6	550
77	Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis. *PLoS ONE*, **2014**, 9, e103716	3.7	10
76	Epitope spreading as an early pathogenic event in pediatric multiple sclerosis. *Neurology*, **2014**, 83, 2219-26	8.3	46
75	Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis. *Neurology*, **2014**, 82, 2173-9	6.5	39
74	Treatment satisfaction in multiple sclerosis. *International Journal of MS Care*, **2014**, 16, 68-75	2.3	26
73	Epidemiology and Genetics **2012**, 56-76		1

72	Disease Pathogenesis **2012**, 1-25		1
71	Pediatric Multiple Sclerosis and Acute Disseminated Encephalomyelitis **2012**, 101-135		
70	Magnetic Resonance Imaging in Multiple Sclerosis **2012**, 136-162		
69	Oral tolerance. *Immunological Reviews*, **2011**, 241, 241-59	11.3	428
68	Reply to Detecting oxysterols in the human circulation *Nature Immunology*, **2011**, 12, 577-578	19.1	1
67	Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. *Journal of Clinical Immunology*, **2010**, 30, 167-77	5.7	61
66	TGF- nduces surface LAP expression on murine CD4 T cells independent of Foxp3 induction. *PLoS ONE*, **2010**, 5, e15523	3.7	53
65	Smoking and disease progression in multiple sclerosis. *Archives of Neurology*, **2009**, 66, 858-64		142
64	The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease?. *Annals of Neurology*, **2009**, 65, 239-48	9.4	276
63	Novel CD8+ Treg suppress EAE by TGF-beta- and IFN-gamma-dependent mechanisms. *European Journal of Immunology*, **2009**, 39, 3423-35	6.1	71
62	Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. *Archives of Neurology*, **2008**, 65, 1449-53		48
61	Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. *Journal of Immunology*, **2008**, 180, 7327-37	5.3	117
60	A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. *Journal of Neurology*, **2008**, 255 Suppl 1, 3-11	5.5	157
59	Cutting Edge: Immature human dendritic cells express latency-associated peptide and inhibit T cell activation in a TGF-beta-dependent manner. *Journal of Immunology*, **2007**, 178, 4017-21	5.3	74
58	A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. *Autoimmunity Reviews*, **2006**, 5, 532-6	13.6	110
57	Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. *Nature Medicine*, **2006**, 12, 627-35	50.5	208
56	Immunology and immunotherapy of Alzheimer's disease. *Nature Reviews Immunology*, **2006**, 6, 404-16	36.5	262
55	Oral tolerance. *Immunological Reviews*, **2005**, 206, 232-59	11.3	578

54	Magnetic Resonance Imaging Surrogates of Multiple Sclerosis Pathology and Their Relationship to Central Nervous System Atrophy. *Journal of Neuroimaging*, **2004**, 14, 46S-53S	2.8	11
53	Current issues in the treatment of human diseases by mucosal tolerance. *Annals of the New York Academy of Sciences*, **2004**, 1029, 211-24	6.5	48
52	Immunosuppressive treatment in multiple sclerosis. *Journal of the Neurological Sciences*, **2004**, 223, 1-11	3.2	25
51	Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. *Archives of Neurology*, **2004**, 61, 1613-5		190
50	CD4+CD25- T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. *Journal of Immunology*, **2003**, 170, 2516-22	5.3	194
49	Oral tolerance induced by continuous feeding: enhanced up-regulation of transforming growth factor-beta/interleukin-10 and suppression of experimental autoimmune encephalomyelitis. *Journal of Autoimmunity*, **2003**, 20, 135-45	15.5	107
48	Mesenteric lymph nodes are critical for the induction of high-dose oral tolerance in the absence of Peyer's patches. *European Journal of Immunology*, **2002**, 32, 1109-13	6.1	150
47	Quantitative analysis of MRI signal abnormalities of brain white matter with high reproducibility and accuracy. *Journal of Magnetic Resonance Imaging*, **2002**, 15, 203-9	5.6	105
46	Induction of colitis in mice deficient of Peyer's patches and mesenteric lymph nodes is associated with increased disease severity and formation of colonic lymphoid patches. *American Journal of Pathology*, **2002**, 161, 2273-82	5.8	60
45	Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. *Immunological Reviews*, **2001**, 182, 207-14	11.3	686
44	B cell-deficient (mu MT) mice have alterations in the cytokine microenvironment of the gut-associated lymphoid tissue (GALT) and a defect in the low dose mechanism of oral tolerance. *Journal of Immunology*, **2001**, 166, 4456-64	5.3	82
43	Nasal administration of amyloid-□peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. *Annals of Neurology*, **2000**, 48, 567-579	9.4	295
42	Nasal administration of amyloid-□peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease **2000**, 48, 567		2
41	Genetic susceptibility or resistance to autoimmune encephalomyelitis in MHC congenic mice is associated with differential production of pro- and anti-inflammatory cytokines. *International Immunology*, **1999**, 11, 1573-80	4.9	55
40	QTL influencing autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing Il2. *Nature Genetics*, **1999**, 21, 158-60	36.3	116
39	Seasonal variation of interferon-gamma production in progressive multiple sclerosis. *Annals of Neurology*, **1998**, 44, 824-8	9.4	41
38	IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. *European Journal of Immunology*, **1998**, 28, 2780-90	6.1	199
37	Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. *Annals of Neurology*, **1997**, 42, 313-8	9.4	78

36	Oral tolerance: elucidation of mechanisms and application to treatment of autoimmune diseases. *Biopolymers*, **1997**, 43, 323-35	2.2	16
35	Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial. *Annals of the New York Academy of Sciences*, **1996**, 778, 243-50	6.5	24
34	Immunologic mechanisms and therapy in multiple sclerosis. *Immunological Reviews*, **1995**, 144, 75-107	11.3	128
33	Peripheral deletion of antigen-reactive T cells in oral tolerance. *Nature*, **1995**, 376, 177-80	50.4	698
32	Suppression of antigen-induced arthritis in Lewis rats by oral administration of type II collagen. *Arthritis and Rheumatism*, **1995**, 38, 1092-6		64
31	Reciprocal expression of co-stimulatory molecules, B7-1 and B7-2, on murine T cells following activation. *European Journal of Immunology*, **1995**, 25, 207-11	6.1	69
30	Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals. *European Journal of Immunology*, **1994**, 24, 1026-32	6.1	102
29	Different kinetic patterns of cytokine gene expression in vivo in orally tolerant mice. *European Journal of Immunology*, **1994**, 24, 2720-4	6.1	44
28	Treatment of autoimmune diseases by oral tolerance to autoantigens. *Autoimmunity*, **1993**, 15 Suppl, 6-7	3	8
27	Common T-cell receptor V beta usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis. *Annals of Neurology*, **1991**, 29, 33-40	9.4	61
26	Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin antigens: IV. Suppression of chronic relapsing disease in the Lewis rat and strain 13 guinea pig. *Annals of Neurology*, **1991**, 29, 615-22	9.4	70
25	T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. *Nature*, **1990**, 346, 183-7	50.4	787
24	Decrease of suppressor inducer (CD4+2H4+) T cells in multiple sclerosis cerebrospinal fluid. *Annals of Neurology*, **1989**, 25, 494-9	9.4	59
23	Loss of functional suppression is linked to decreases in circulating suppressor inducer (CD4+ 2H4+) T cells in multiple sclerosis. *Annals of Neurology*, **1988**, 24, 185-91	9.4	69
22	Gene activation during experimental allergic encephalomyelitis. Cloning of new cDNAs. *Annals of the New York Academy of Sciences*, **1988**, 540, 264-5	6.5	1
21	Immunohistochemical analysis of suppressor-inducer and helper-inducer T cells in multiple sclerosis brain tissue. *Annals of the New York Academy of Sciences*, **1988**, 540, 306-8	6.5	2
20	Loss of functional suppression is linked to decreases in circulating suppressor-inducer (CD4+ 2H4+) T cells in multiple sclerosis. *Annals of the New York Academy of Sciences*, **1988**, 540, 330-2	6.5	4
19	Cumulative experience with high-dose intravenous cyclophosphamide and ACTH therapy in chronic progressive multiple sclerosis. *Annals of the New York Academy of Sciences*, **1988**, 540, 535-6	6.5	3

18	Role of mast cells in peripheral nervous system demyelination. *Annals of the New York Academy of Sciences*, **1988**, 540, 727-8	6.5	11
17	Type 1 human poliovirus binds to human synaptosomes. *Annals of Neurology*, **1987**, 21, 64-70	9.4	25
16	In vivo labeling of blood T cells: rapid traffic into cerebrospinal fluid in multiple sclerosis. *Annals of Neurology*, **1987**, 22, 89-93	9.4	83
15	Antiidiotypic antibody to reovirus binds to neurons and protects from viral infection. *Annals of Neurology*, **1986**, 19, 555-8	9.4	17
14	Immunohistochemical analysis of the cellular infiltrate in multiple sclerosis lesions. *Annals of Neurology*, **1986**, 19, 578-87	9.4	309
13	Infection of neuronal cell cultures with reovirus mimics in vitro patterns of neurotropism. *Annals of Neurology*, **1984**, 16, 603-10	9.4	49
12	Immunoregulatory T-cells and lymphocytotoxic antibodies in active multiple sclerosis: weekly analysis over a six-month period. *Annals of Neurology*, **1983**, 13, 418-25	9.4	85
11	Age dependent susceptibility to Reovirus type 3 encephalitis: role of viral and host factors. *Annals of Neurology*, **1983**, 13, 602-7	9.4	71
10	Clonally restricted B cells in peripheral blood of multiple sclerosis patients: kappa/lambda staining patterns. *Annals of Neurology*, **1982**, 11, 408-12	9.4	10
9	Neuroimmunology I: Immunoregulation in neurological disease. *Annals of Neurology*, **1982**, 11, 437-49	9.4	93
8	Childhood multiple sclerosis: clinical features and demonstration of changes in T cell subsets with disease activity. *Annals of Neurology*, **1982**, 11, 463-8	9.4	52
7	Biomarkers26-55		
6	Cognitive Dysfunction in Multiple Sclerosis239-262		
5	Future Therapeutic Approaches283-300		
4	Medication Treatment in Multiple Sclerosis181-212		
3	Depression and Other Psychosocial Issues in Multiple Sclerosis263-282		2
2	Predicting Clinical Course163-180		1
1	Symptom Management213-238		1